Elucid Closes $55M Series D as Its Plaque-Reading AI Pushes Toward Wider Cardiac Use
Boston-based Elucid raised $55 million in an oversubscribed Series D, pushing total funding to roughly $185 million, to scale its FDA-cleared Plaque-IQ software and push its BioIntegrated FFR-CT tool through regulatory review.